Published in Aging Cell on June 07, 2013
Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell (2014) 2.35
Rapamycin ameliorates nephropathy despite elevating hyperglycemia in a polygenic mouse model of type 2 diabetes, NONcNZO10/LtJ. PLoS One (2014) 1.41
Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell (2014) 1.14
Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging (Albany NY) (2014) 1.12
Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance. Aging (Albany NY) (2013) 1.07
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis (2013) 1.04
Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis (2014) 1.01
eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) (2013) 0.99
Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol Aging (2013) 0.94
Koschei the immortal and anti-aging drugs. Cell Death Dis (2014) 0.93
Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. J Gerontol A Biol Sci Med Sci (2016) 0.90
Organization of the Mammalian Metabolome according to Organ Function, Lineage Specialization, and Longevity. Cell Metab (2015) 0.88
Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life. PLoS One (2015) 0.88
Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice. Aging Cell (2015) 0.88
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS One (2014) 0.88
Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell (2015) 0.87
Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY) (2015) 0.86
eIF6 coordinates insulin sensitivity and lipid metabolism by coupling translation to transcription. Nat Commun (2015) 0.86
Rapamycin and dietary restriction induce metabolically distinctive changes in mouse liver. J Gerontol A Biol Sci Med Sci (2014) 0.85
Rapamycin Versus Intermittent Feeding: Dissociable Effects on Physiological and Behavioral Outcomes When Initiated Early and Late in Life. J Gerontol A Biol Sci Med Sci (2015) 0.84
Lifespan modulation in mice and the confounding effects of genetic background. J Genet Genomics (2014) 0.84
Diminished mTOR signaling: a common mode of action for endocrine longevity factors. Springerplus (2014) 0.84
Chronic rapamycin treatment causes diabetes in male mice. Am J Physiol Regul Integr Comp Physiol (2014) 0.83
Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice. Front Mol Neurosci (2014) 0.80
Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes. Aging (Albany NY) (2016) 0.75
Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions. Curr Top Med Chem (2015) 0.75
Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks. EBioMedicine (2016) 0.75
Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Use and abuse of HOMA modeling. Diabetes Care (2004) 16.97
Economic costs of diabetes in the US in 2002. Diabetes Care (2003) 8.92
Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care (1998) 8.29
Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science (2009) 7.80
mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 7.12
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci (2010) 5.54
mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal (2009) 3.94
Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J (2007) 3.83
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol (2008) 2.59
Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (IRS)-1 and IRS-2 in liver of Ames dwarf mice. J Endocrinol (2002) 1.94
Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol (2005) 1.49
Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci (2010) 1.34
Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl) (2011) 1.32
Surrogate measures of insulin resistance: of rats, mice, and men. Am J Physiol Endocrinol Metab (2009) 1.23
Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab (2012) 1.20
Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice. J Gerontol A Biol Sci Med Sci (2012) 1.07
Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med (2013) 1.01
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
mTOR signaling in growth control and disease. Cell (2012) 29.21
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
CellProfiler: free, versatile software for automated biological image analysis. Biotechniques (2007) 14.71
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell (2007) 6.47
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab (2008) 6.22
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci (2010) 5.54
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J (2012) 5.03
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J (2007) 4.66
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature (2010) 3.81
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell (2012) 3.77
Rapamycin slows aging in mice. Aging Cell (2012) 3.76
SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab (2012) 3.69
Tumours with PI3K activation are resistant to dietary restriction. Nature (2009) 3.60
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 3.50
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell (2010) 3.33
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell (2009) 3.16
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
CellProfiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinformatics (2008) 2.99
Systematic genome-wide screens of gene function. Nat Rev Genet (2004) 2.92
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells. Nat Methods (2004) 2.72
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell (2008) 2.65
TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab (2012) 2.59
An Aging Interventions Testing Program: study design and interim report. Aging Cell (2007) 2.54
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med (2012) 2.38
Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell (2014) 2.35
Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. Nature (2012) 2.28
Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell (2011) 2.24
Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci (2013) 2.22
Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods (2006) 2.18
Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol (2006) 2.06
Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem (2005) 2.00
Rapamycin inhibits mTORC1, but not completely. Autophagy (2009) 1.99
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov (2014) 1.99
Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell (2006) 1.93
Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem (2005) 1.89
The Snell dwarf mutation Pit1(dw) can increase life span in mice. Mech Ageing Dev (2002) 1.87
SRT1720 improves survival and healthspan of obese mice. Sci Rep (2011) 1.81
mTOR Signaling. Cold Spring Harb Perspect Biol (2012) 1.79
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74